Monitoring ecstasy content in France: Results from the National Surveillance System 1999-2004

Substance Use and Misuse

Volumn 42, Issue 10, 2007, Pages 1567-1578

  Giraudon, Isabelle ^a,b   Bello, Pierre Yves ^a  

^a Observ Francais des Drogues et Toxicomanies (Fr Monitoring Centre for Drugs and Drug Addiction)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Early warning; Ecstasy; Europe; Harm reduction; Illicit drugs; Networks; Prevention; Surveillance system; Synthetic drugs; Trends

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CAFFEINE; ILLICIT DRUG; PSYCHOTROPIC AGENT;

ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DATA COLLECTION METHOD; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; FRANCE; HUMAN; LAW ENFORCEMENT; PRIORITY JOURNAL; PUBLIC HEALTH; SOCIAL WORKER; TABLET;

CAFFEINE; DRUG AND NARCOTIC CONTROL; EMIGRATION AND IMMIGRATION; FRANCE; HALLUCINOGENS; HUMANS; LAW ENFORCEMENT; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POLICE; QUESTIONNAIRES; SOCIAL WORK; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; TABLETS;

EID: 35148877795     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.1080/10826080701212428     Document Type: Article

References (23)

1. Beck, F., Legleye, S., Spilka, S. (2004a). Cannabis, alcool, tabac et autres drogues à la fin de l'adolescence: usages et évolutions récentes [Cannabis, alcohol, tobacco and other drugs at the end of teen-age: Uses and recent evolutions]. Tendances 39:1-4.
2. Beck, F., Legleye, S., Spilka, S. (2004b). Drogues à l'adolescence: niveaux et contextes d'usage de cannabis, alcool, tabac et autres drogues à 17-18 ans en France [Drugs in teen-age: Level and contexts of use for cannabis, alcohol, tobacco and others drugs at 17-18 years in France]. Paper presented at Escapad 2003, OFDT, Saint Denis.
3. Bell, S. E., Barrett, L. J., Burns, D. T., Dennis, A. C., Speers, S. J. (2003). Tracking the distribution of "ecstasy" tablets by Raman composition profiling: A large-scale feasibility study, Analyst 128:1331-1335.
4. Bello, P.-Y., Toufik, A., Gandilhon, M., Giraudon, I., Bonnet, N. (2004, June). Phénomènes émergents liés aux drogues en 2003. Cinquième rapport national du dispositif TREND [Emerging trends in drugs in 2003. Fifth national report of the TREND scheme]. Paper presented at OFDT, Paris.
5. Dean, A. G., Arner, T. G., Sunki, G. G., Friedman, R., Lantinga, M., Sangam, S., et al. (2002). Epi Info™, a database and statistics program for public health professionals. Atlanta: Centers for Disease Control and Prevention.
6. Delille, J.-M., Gachie, J.-P. (2002). Ecstasy et réduction des risques: la place du testing et des analyses de substances [Ecstasy and harm reduction: Testing and substances analysis]. Alcoologie et Addictologie 24:311-318.
7. European Monitoring Centre for Drug and Drug Addiction. (2004). Annual report 2004: The state of the drugs problem in the European Union and Norway. Lisbon: Author.
8. European Union. (1997). Joint Action of 16 June 1997 adopted by the Council on the basis of Article K.3 of the Treaty on European Union, concerning the information exchange, risk assessment and the control of new synthetic drugs. 97/396/JHA (OJEU L 167 of 25.6. 1997, p.1).
9. Giraudon, I., Bello, P.-Y. (2003). Regards sur l'ecstasy et d'autres produits de synthèse en France. Analyse de la base du système d'identification national des toxiques et des substances (SINTES) de 1999 à la fin du premier semestre 2002 [Overview of ecstasy and other synthetic drugs in France. Data analysis of the National Identification System for Drugs and Other Substances (SINTES) from 1999 to the first half of 2002]. Paper presented at OFDT, Paris.
10. Holland, J. (2001). The history of MDMA. In J. Holland (Ed.). Ecstasy: The complete guide, pp. 11-21. Rochester, NY: Park Street Press.
11. Institut national de la santé et de la recherche médicale. (1998). Ecstasy: des données biologiques et cliniques aux contextes d'usage [Ecstasy: From biological and clinical data to context of use]. Paris, INSERM (Institut national de la santé et de la reserche médicale) [National Institute for Health and Medical Research], 1998.
12. MILDT (Inter-departmental mission for the fight against drugs and drug addiction). (1999). Plan triennal de Lutte contre la drogue et de prévention des dépendances 1999-2000-2001 [Three-year plan to combat drug use and to prevent dependence (1999-2001)], La Documentation Français, Paris.
13. OCTRIS (Office central de répression du trafic illicite des stupéfiants). (2004). Usage et trafic des produits stupéfiants en France en 2003 [Use and deal of ilicit substances in France in 2003]. DGPN/DGPJ, Nanterre 1-116.
14. OFDT/SINTES. SINTES Informations rapides [Rapid information]. (2003). Retrieved from http://www.ofdt.fr/BDD/sintes/notes.htm
15. Parrott, A. C. (2004). Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity, Psychopharmacology 173:234-241.
16. Piljman, F. T. A., Krul, J., Niesink, R. J. M. (2003). Uitgaan en Veiligheid: feiten en fictie over alcohol, drugs en gezondheidsverstoringen [Clubbing and safety: facts and fiction on alcohol, drugs ans health problems]. Utrecht, The Netherlands: Trimbos-Institute.
17. Reynaud-Maurupt, C., Akoka, S. (2004, June). Les usages détournés de la kétamine en France en 2001-2003. "Ket-riding" ou les nouveaux voyages immobiles [Misuse of ketamine in France in 2001-2003. "Ket-riding" or the new immobiles trips]. Paper presented at OFDT, Paris.
18. Sarradet, A., Toufik, A., Gandilhon, M. (2000, March). Tendances récentes: rapport TREND [Recent trends: Rapport TREND]. Paper presented at OFDT, Paris.
19. SINTES/OFDT. (2002, December). Nouvelle identification de PMA; information rapide SINTES [New identification of PMA; SINTES Rapid Information]. Paper presented at OFDT, Paris.
20. SINTES/OFDT. (2004, June). Médicament ou ecstasy? Comprimés collectés dans le cadre de SINTES, a la fin du premier trimestre 2004; information rapide SINTES [Medicinal products or ecstasy? Tablets collected through SINTES to the end of the first quarter in 2004. SINTES; SINTES rapid Information]. Paper presented at OFDT, Paris.
21. SINTES/OFDT. (2004, October). Comprimés et gélules fortement dosés en MDMA; information rapide SINTES [Tablets and capsules with high MDMA dosage. SINTES rapid information]. Paper presented at OFDT, Paris.
22. Sueur, C. (2004). Eduquer le toxicomane [Educate the drug-user], Psychotrope 10:47-79.
23. Sueur, C., Bastiannelli, M. (1999). Usages de drogues de synthèse et réduction des risques en milieu festif techno [Synthetic drug use (Ecstasy, LSD, dance-pills, amphétamines...) and harm reduction in techno scene]. Paris: Médecins du Monde.